Company profile: Semnur Pharma
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical development focused on the clinical and commercial advancement of innovative products for pain management, including SP-102 (SEMDEXA), a non-opioid injectable corticosteroid gel designed to treat moderate to severe chronic radicular pain/sciatica via epidural injection.
Products and services
- Clinical Development of Innovative Pain Management Products: Advances clinical development for innovative therapies that meet pain management practitioners’ and patients’ needs, specialty pharmaceutical-focused programs
- Commercial Development of Innovative Pain Management Products: Orchestrates commercial development for innovative products serving pain management practitioners and patients, specialty pharmaceutical-directed initiatives across commercialization
- SP-102 (SEMDEXA™): Non-opioid injectable corticosteroid gel formulation engineered for epidural administration to treat moderate to severe chronic radicular pain/sciatica, administered via epidural injection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Semnur Pharma
Curemark
HQ: United States
Website
- Description: Provider of socially-driven biotechnology therapies for neurological diseases, developing CM-AT for Autism Spectrum Disorder (enhancing protein digestion and potentially restoring essential amino acids), CM-4612 (Phase III-ready for ADHD), CM-182 (enzyme replacement therapy for schizophrenia), CM-PK (for Parkinson’s, potentially affecting dopamine), and CM-1212 (for substance use disorders).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curemark company profile →
Aderis Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical products for the diagnosis and treatment of cardio-renal and cardiovascular diseases, including adenosine agonists and antagonists; focused on discovery, development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aderis Pharmaceuticals company profile →
Cosman Medical
HQ: United States
Website
- Description: Provider of radiofrequency (RF) generators, electrodes, and cannulae for neurosurgery and pain management in interventional anesthesiology and podiatry, leveraging RF nerve ablation with a 60-year track record in medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cosman Medical company profile →
SiteOne Therapeutics
HQ: United States
Website
- Description: Provider of novel non-opioid therapeutics and diagnostics for acute and chronic pain, including STC-004, an investigational NaV1.8-selective treatment; ST-2427, a highly selective NaV1.7 inhibitor for moderate-to-severe pain administered intravenously; and an inhaled NaV1.7-targeting therapy for chronic cough to reduce nerve fiber sensitivity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SiteOne Therapeutics company profile →
Cerevance
HQ: United States
Website
- Description: Provider of therapeutics for CNS disorders, leveraging its NETSseq platform to identify novel targets. Pipeline includes CVN424, a first-in-class compound targeting a novel receptor with phase 2 efficacy in Parkinson’s disease; CVN766, a selective orexin 1 antagonist for psychiatric conditions focused on avoiding somnolence; and CVN293, a KCNK13 inhibitor under investigation for ALS and Alzheimer’s.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerevance company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Semnur Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Semnur Pharma
2.2 - Growth funds investing in similar companies to Semnur Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Semnur Pharma
4.2 - Public trading comparable groups for Semnur Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →